DUXAP9 has been explored as an oncogene promoting the tumor progression in bladder cancer (10), thyroid cancer (24), non‐small cell lung cancer (25) as well as the growth of renal cell carcinoma (26). Here, DUXAP9 is linked to urinary bladder cancer.